Find Clinical Trial

Home » Find Clinical Trials » Clinical non-inferiority study between Daflon 1000 mg, one oral suspension in a sachet per day and Daflon 500 mg, 2 tablets daily after eight weeks of treatment in patients suffering from symptomatic Chronic Venous Disease (CVD). International, multicenter, double-blind, randomized, parallel group study

Clinical non-inferiority study between Daflon 1000 mg, one oral suspension in a sachet per day and Daflon 500 mg, 2 tablets daily after eight weeks of treatment in patients suffering from symptomatic Chronic Venous Disease (CVD). International, multicenter, double-blind, randomized, parallel group study

← Back

Study Phase	Phase 3

Therapeutic Area	Cardiovascular Diseases

Indication	venous disease

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S)

Active substance/ Medical device	MICRONISED PURIFIED FLAVONOID FRACTION, S005682

Active Substance Code	S005682

Protocol Code	CL3-05682-105

EudraCT Code	2012-003559-13

Documents and links

Lay summary

Results summary	READ MORE

Scientific publication	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.